What is it about?
Here, we present an extensive panel of clinical specimens to systematically evaluate the technical sensitivity of SARS-CoV-2 antigen rapid detection tests
Featured Image
Photo by Annie Spratt on Unsplash
Why is it important?
Currently, there are no standardized methods to evaluate the performance of SARS-CoV-2 rapid antigen detection tests. This makes comparison of performance between tests difficult, if not impossible. However, the here presented specimen panel can be used for the evaluation of technical sensitivity of SARS-CoV-2 antigen rapid detection tests.
Perspectives
Until now, the specimen panel has been successfully used in the evaluation of 122 SARS-CoV-2 rapid antigen detection tests distributed in the EU. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.44.2100441 Currently, we are working on further improving the current specimen panel to also include specimens for the evaluation of rapid antigen detection test specificity.
Andreas Puyskens
Robert Koch Institute
Read the Original
This page is a summary of: Establishment of a specimen panel for the decentralised technical evaluation of the sensitivity of 31 rapid diagnostic tests for SARS-CoV-2 antigen, Germany, September 2020 to April 2021, Eurosurveillance, November 2021, European Centre for Disease Control and Prevention (ECDC),
DOI: 10.2807/1560-7917.es.2021.26.44.2100442.
You can read the full text:
Resources
Contributors
The following have contributed to this page
